Liang Cheng: Should Pathologists Continue to Consider Grade Group 1 Prostate Cancer as a True Carcinoma?
Liang Cheng, Vice Chair for Translational Research at Warren Alpert Medical School of Brown University, President of the International Society of Urologic Pathology, shared a post on LinkedIn about recent paper he and colleagues co-authored published in Italian Archives of Urology and Andrology.
“Should pathologists and clinicians continue to consider Grade Group 1 (Gleason score ≤6) prostate cancer as a true carcinoma?
Let’s hear from patient advocates – PubMed – an excellent and insightful editorial from Prof. Montironi.”
Title: Should pathologists and clinicians continue to consider Grade Group 1 (Gleason score ≤6) prostate cancer as a true carcinoma? Let’s hear from patient advocates
Authors: Rodolfo Montironi, Alessia Cimadamore, Antonio Lopez-Beltran, Eamonn T. Rogers, Liang Cheng
Read The Full Article at Italian Archives of Urology and Andrology.
More posts featuring Liang Cheng.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023